Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Open accessThe DOI matches its Crossref record; 130 of the 132 references it cites were found in a registry or an index; 128 of the 188 sources its claims cite were checked for support.
Abstract
The advent of induced pluripotent stem cells (iPSCs) has advanced our understanding of the molecular mechanisms of human disease, drug discovery, and regenerative medicine. As such, the use of iPSCs in drug development and validation has shown a sharp increase in the past 15 years. Furthermore, many labs have been successful in reproducing many disease phenotypes, often difficult or impossible to capture, in commonly used cell lines or animal models. However, there still remain limitations such as the variability between iPSC lines as well as their maturity. Here, we aim to discuss the strategies in generating iPSC-derived cardiomyocytes and neurons for use in disease modeling, drug development and their use in cell therapy.
Overview
CoChat Summary
TL;DR
This review discusses how induced pluripotent stem cell (iPSC)-derived cardiomyocytes, neurons, and organoids are used for disease modeling, drug discovery, and cell therapy, with emphasis on cardiovascular and neurological applications. It also covers remaining hurdles including iPSC line variability, cell immaturity, and immune rejection in transplantation.
Key findings
- iPSC-derived cardiomyocytes recapitulate cardiac channelopathies and cardiomyopathies and have enabled drug discovery: e.g., nicorandil and PD118057 shortened action potentials in type-2 LQTS cells, mexiletine analogues enhanced INa potency/selectivity for type-3 LQTS, and verapamil showed the strongest inhibition of contractile function among four calcium channel blockers tested in HCM cells.
- iPSC-derived neurons model AD, PD, ALS, ASD, and SMA; examples include docosahexaenoic acid alleviating stress responses in AD neurons, Coenzyme Q10/rapamycin/GW5074 in LRRK2- and PINK1-mutant PD cells, ropinirole in TDP-43/FUS ALS motor neurons, and IGF-1 or hyperforin rescuing TRPC6-mutant ASD neuronal abnormalities.
- Organoid platforms support screening: >10,000 cardiac organoids were screened to identify optimal maturation conditions; >1000 FDA-approved drugs were screened in hPSC-forebrain organoids, identifying hippeastrine hydrobromide against ZIKV; a 50,000-compound screen in fragile X neuronal progenitors identified compounds inducing FMRP expression.
- HLA-homozygous iPSC banking can cover large populations from few donors: 55 donors for ~80% of the Japanese population, 150 iPSC lines for ~93% of the UK, 140 lines for ~90% of Japan, and ~80 lines for 50% coverage in California; CiRA's three clinical-grade lines cover 32% of Japan, Korea's 10 lines cover 41%, and Taiwan's 13 lines cover ~16% of Taiwanese.
Methods
- Narrative review (no primary data collection) covering iPSC generation and differentiation into cardiomyocytes, neurons, and organoids for disease modeling, drug discovery, and cell therapy.
- Synthesizes published preclinical and clinical studies, including high-throughput screening studies, HLA banking calculations, and CRISPR/Cas9 genome-editing approaches.
- Includes a table (Table 1) outlining iPSC-based clinical trials current as of 2021.
Limitations
- Stated by the paper: iPSC-derived cells are immature and lack intercellular communication, making complex adult disease mimicry difficult; many diseases are polygenic/heterogeneous (e.g., ASD) so a single patient line may not yield a single hit compound; reprogramming and differentiation protocol reproducibility is a recurring issue; 5–46% of phenotypic variability in iPSCs stems from normal human genetic variation (inter- and intraclone); high-throughput miniaturization challenges include low cell numbers, media evaporation, and low-volume dispensing accuracy; organoids represent fetal-like rather than adult structures; CRISPR/Cas9 off-target cleavage risks oncogenic mutations; HLA-edited cells carry increased tumorigenicity risk; autologous transplantation is time-consuming and expensive.
- Evident from the text: the review is descriptive and does not present new experimental data; several cited clinical trials (e.g., Help Therapeutics Phase 1/2, Cuorips/Osaka Phase 1) lacked efficacy data at the time of writing.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
87 Valid · 19 Not valid · 34 Not checked · 39 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Using iPSC-derived cardiomyocytes from type-3 LQTS patients with SCN5A mutation revealed abnormal calcium transients with diminished INa current density [11].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 2. Drug Discovery Using iPSC-Derived Disease Models > 2.1. Cardiomyocytes
What the sources say
- Disputedcites [11] Hong L. Zhang M. Ly O.T. Chen H. Sridhar A. Lambers E. Chalazan B. Youn S.-W. Maienschein-Cline M. Feferman L. Human induced pluripotent stem cell-derived atrial cardiomyocytes carrying an SCN5A mutation identify nitric oxide signaling as a mediator of atrial fibrillation Stem Cell Rep. 2021 16 1542 1554 10.1016/j.stemcr.2021.04.019 34019817 PMC8190590 sourceExperimental — accuracy not yet measured
The Results section on AF iPSC-aCMs reports abnormal calcium transients in SCN5A-mutant atrial cardiomyocytes, but these were studied in an atrial-fibrillation model, not cells from type-3 LQTS patients. The same section reports no significant change in sodium-current amplitude and a marked increase in late sodium current (INa,L), contrary to the claimed diminished INa current density. Page numbers are unavailable in our copy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The capacity of iPSCs for the scalable production of diverse cell types benefits researchers by reducing obstacles with procedures such as apheresis, which involves separating specific components from the blood and retuning the remaining components to the donor’s circulation, whilst obtaining human cells [3].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 1. Introduction
What the sources say
- Partly supportedcites [3] Carvajal-Vergara X. Sevilla A. D’Souza S.L. Ang Y.S. Schaniel C. Lee D.F. Yang L. Kaplan A.D. Adler E.D. Rozov R. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome Nature 2010 465 808 812 10.1038/nature09005 20535210 PMC2885001 sourceExperimental — accuracy not yet measured
The paper reports that patient-derived iPSCs differentiated into multiple cell types and describes iPSC-derived cells as a resource for studying disease (Abstract; page unavailable). It does not establish scalable production or say that iPSCs reduce obstacles associated with apheresis; its patient cells were obtained from skin biopsies (Methods Summary, Cell culture; page unavailable). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Various cell models built with iPSC derivatives have been shown to resemble in vivo or primary cell counterparts at transcriptional, cellular, and functional levels whilst leaving little interference to the genetic content [4,5,6,7].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 1. Introduction
What the sources say
- Partly supportedcites [4] Caspi O. Huber I. Gepstein A. Arbel G. Maizels L. Boulos M. Gepstein L. Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells Circ. Cardiovasc. Genet. 2013 6 557 568 10.1161/CIRCGENETICS.113.000188 24200905 sourceExperimental — accuracy not yet measured
The Generation of the ARVC Patient-Specific hiPSCs section reports that the cells retained the patient’s PKP2 mutation and had a normal karyotype. CM Differentiation reports cardiac gene expression, cell markers, and electrical activity; the Discussion says the derived cells reproduced key ARVC pathology. These findings support resemblance in this disease model, but the paper does not establish that producing iPSC-derived models causes little interference with genetic content generally. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [5] Moretti A. Bellin M. Welling A. Jung C.B. Lam J.T. Bott-Flügel L. Dorn T. Goedel A. Höhnke C. Hofmann F. Patient-specific induced pluripotent stem-cell models for long-QT syndrome N. Engl. J. Med. 2010 363 1397 1409 10.1056/NEJMoa0908679 20660394 source
- Not checked — no full text of the sourcecites [6] Egashira T. Yuasa S. Suzuki T. Aizawa Y. Yamakawa H. Matsuhashi T. Ohno Y. Tohyama S. Okata S. Seki T. Disease characterization using LQTS-specific induced pluripotent stem cells Cardiovasc. Res. 2012 95 419 429 10.1093/cvr/cvs206 22739119 source
- Not checked — no full text of the sourcecites [7] Itzhaki I. Maizels L. Huber I. Zwi-Dantsis L. Caspi O. Winterstern A. Feldman O. Gepstein A. Arbel G. Hammerman H. Modelling the long QT syndrome with induced pluripotent stem cells Nature 2011 471 225 229 10.1038/nature09747 21240260 source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Even though rigorous testing is undertaken during the development stages, 90% of drugs fail clinical trials [2].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 1. Introduction
What the sources say
- Could not verifycites [2] Li S. Pan H. Tan C. Sun Y. Song Y. Zhang X. Yang W. Wang X. Li D. Dai Y. Mitochondrial Dysfunctions Contribute to Hypertrophic Cardiomyopathy in Patient iPSC-Derived Cardiomyocytes with MT-RNR2 Mutation Stem Cell Rep. 2018 10 808 821 10.1016/j.stemcr.2018.01.013 PMC5918198 29456182 sourceExperimental — accuracy not yet measured
The Introduction discusses the difficulty of obtaining patient cardiomyocytes, and the Experimental Procedures describe cell-based experiments; neither addresses clinical-trial outcomes. Searches for the 90% figure and for drug-development failure rates found no supporting passage in our copy. (LLM, conf=0.75)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The physiological and genetic differences between human and animals leads to potential differences in terms of function, mechanisms, and signaling pathways [14,15].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 2. Drug Discovery Using iPSC-Derived Disease Models
What the sources say
- Partly supportedcites [14] Lan F. Lee A.S. Liang P. Sanchez-Freire V. Nguyen P.K. Wang L. Han L. Yen M. Wang Y. Sun N. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells Cell Stem Cell 2013 12 101 113 10.1016/j.stem.2012.10.010 23290139 PMC3638033 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) explains that human and mouse hearts predominantly use different myosin isoforms and that the same HCM mutation can have different functional consequences in those isoforms. This supports the claim about potential functional differences, but the paper does not establish a general human–animal difference in mechanisms or signaling pathways. (LLM, conf=0.86)
- Partly supportedcites [15] Han L. Li Y. Tchao J. Kaplan A.D. Lin B. Li Y. Mich-Basso J. Lis A. Hassan N. London B. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells Cardiovasc. Res. 2014 104 258 269 10.1093/cvr/cvu205 25209314 PMC4217687 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that mouse models cannot represent the genetic diversity of human hypertrophic cardiomyopathy and that patient-specific disease mechanisms need study. It does not establish that physiological differences between humans and animals cause differences in function or signaling pathways. (LLM, conf=0.82)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
100 more claims · 53 with their cited sources checked
Create a free account to see all 179 claims and every source verdict.
- It may state two separate claims as one. 54
- Probably not a substantial claim. 27
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 3. iPSC-Based Cell Therapy > 3.1. HLA-Homozygous iPSC Banking
“This was confirmed in mice showing that iPSC-derived cell implantation leads to cellular apoptosis and T cell proliferation [94].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > References
“94. Guha P. Morgan J.W. Mostoslavsky G. Rodrigues N.P. Boyd A.S. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells Cell Stem Cell 2013 12 407 412”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 2. Drug Discovery Using iPSC-Derived Disease Models > 2.2. Neurons
“Ohuchi et al., 2006, first used SMA patient iPSC-derived motor neurons and astrocytes”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > References
“51. Ohuchi K. Funato M. Kato Z. Seki J. Kawase C. Tamai Y. Ono Y. Nagahara Y. Noda Y. Kameyama T. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog Stem Cells Transl. Med. 2016 5 152 163”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 3. iPSC-Based Cell Therapy
“Other notable Phase 1 clinical trials in Japan includes an iPSC-derived cardiomyocyte sheet from a group comprising Cuorips Inc. and Osaka University [90]; their preclinical studies on ischemic cardiomyopathy pig models have shown improved cardiac function”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > References
“90. Doi D. Magotani H. Kikuchi T. Ikeda M. Hiramatsu S. Yoshida K. Amano N. Nomura M. Umekage M. Morizane A. Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson’s disease Nat. Commun. 2020 11 3369”
Citations
Cites
Cerebral organoids model human brain development and microcephaly
Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372 · cited 1×
“These 3D “organoids” are often found to have instructive morphogenetic cues resulting in self organization similarly found in vivo [53,54].”
BackgroundDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380 · cited 1×
“NK cells, which act as important immune cells, are widely used for transplantation [82,83].”
BackgroundDouble nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096 · cited 1×
“These models have been particularly important in the search for anticancer compounds as they can predict patient outcomes in phase 1/2 clinical trials for gastrointestinal cancer [55].”
BackgroundA more efficient method to generate integration-free human iPS cells
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K.-I., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1591 · Cited by 2,061
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624
Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration
Mandai, M., Watanabe, A., Kurimoto, Y., Hirami, Y., Morinaga, C., Daimon, T., Fujihara, M., Akimaru, H., Sakai, N., Shibata, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608368 · Cited by 1,509
Cited by
Wang, L., Wang, B., Wu, C., Wang, J., & Sun, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031819 · Cited by 237
“2 Duplication ↓spontaneous neuronal activity and calcium signalling; ↓expression of miR-1290 [53]”
BackgroundExploring the promising potential of induced pluripotent stem cells in cancer research and therapy
Chehelgerdi, M., Behdarvand Dehkordi, F., Chehelgerdi, M., Kabiri, H., Salehian-Dehkordi, H., Abdolvand, M., Salmanizadeh, S., Rashidi, M., Niazmand, A., Ahmadi, S., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01873-0 · Cited by 175
Revolutionizing Disease Modeling: The Emergence of Organoids in Cellular Systems
Silva-Pedrosa, R., Salgado, A. J., & Ferreira, P. E. (2023) · Cells · doi:10.3390/cells12060930 · Cited by 84
“This can greatly accelerate the drug development process and ultimately lead to new treatments for patients [46,47].”
BackgroundProgress in Organ Bioprinting for Regenerative Medicine
Wang, X. S., Zhang, D., Singh, Y. P., Yeo, M., Deng, G., Lai, J., Chen, F., Ozbolat, I. T., & Yu, Y. (2024) · Engineering · doi:10.1016/j.eng.2024.04.023 · Cited by 70
“Recent studies have differentiated iPSCs into cells of various lineages such as CMs, neurons, hepatic cells, and ECs [85,86], The field of bioprinting has witnessed a trend of utilizing iPSC-derived cells, such as for the fabrication of cardiac [87], hepatic [43], and pancreatic [88] tissues.”
A Review of Advanced Biomaterials and Cells for the Production of Bone Organoid
Li, C., Zhang, Y., Du, Y., Hou, Z., Zhang, Y., Cui, W., & Chen, W. (2023) · Small Science · doi:10.1002/smsc.202300027 · Cited by 34
Martinez, M. G. V., Frauenlob, M., & Rothbauer, M. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2362183 · Cited by 35
“Incorporating induced pluripotent stem cells (iPSCs) into the body-on-a-chip framework enables for the first time personalized drug screening similar to what has proven useful for organoid approaches [61,62].”
BackgroundEngineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform
Fang, Y., Chen, Y., & Li, Y.-R. (2025) · Stem Cell Reports · doi:10.1016/j.stemcr.2025.102515 · Cited by 40
Application Prospect of Induced Pluripotent Stem Cells in Organoids and Cell Therapy
Zhang, T., Qian, C., Song, M., Tang, Y., Zhou, Y., Dong, G., Shen, Q., Chen, W., Wang, A., Shen, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052680 · Cited by 27
“…benefit from iPSCs’ ability to produce a variety of cell types on a large scale by removing barriers related to processes like apheresis, which involves removing certain blood components and returning the remaining components to the donor’s circulation in order to obtain human cells [142].”
BackgroundStem cell therapy in pulmonary hypertension: current practice and future opportunities
Zheng, R., Xu, T., Wang, X., Yang, L., Wang, J., & Huang, X. (2023) · European Respiratory Review · doi:10.1183/16000617.0112-2023 · Cited by 22
Multifactorial approaches to enhance maturation of human iPSC-derived cardiomyocytes
Kistamás, K., Müller, A., Muenthaisong, S., Lamberto, F., Zana, M., Dulac, M., Leal, F., Maziz, A., Costa, P. F., Bernotienė, E., et al. (2023) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2023.122668 · Cited by 17
Management of Pulmonary Arterial Hypertension: Current Strategies and Future Prospects
Sharma, M., Paudyal, V., Syed, S., Thapa, R., Kassam, N., & Surani, S. (2025) · Life · doi:10.3390/life15030430 · Cited by 22
“…are apparent, including those related to tumorigenicity, genetic and epigenetic abnormalities, and long-term safety and efficacy, iPSCs are often used as cell models for investigating different phenotypes, drug screening, RNA sequencing, and the influence of gene mutation [104,108,110,121].”
Mohite, P. B., Puri, A. V., Dave, R., Budar, A., Munde, S. V., Ghosh, S. B., Alqahtani, T., Shmrany, H. A., Kumer, A., & Dhara, B. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001892 · Cited by 24
“…drugs, toxicological study, and disease simulation, have made use of hiPSCs and their derived compounds as they offer a human-relevant cell source [8] . hiPSCs were promptly utilized to establish models representing human diseases in a laboratory setting and for pharmaceutical screening to check…”
BackgroundMethodLu, H., Zuo, X., Yuan, J., Xie, Z., Yin, L., Pu, Y., Chen, Z., & Zhang, J. (2024) · Journal of Applied Toxicology · doi:10.1002/jat.4618 · Cited by 18
“Using human induced pluripotent stem cells (hiPSCs) is essential when a continuous primary cell source is unavailable. hiPSCs have opened new avenues for medical research, thus overcoming the limitations of primary cell cultures (Nicholson et al., 2022).”
The Power of Gene Technologies: 1001 Ways to Create a Cell Model
Karagyaur, M. N., Primak, A. L., Efimenko, A. Y., Никитична, С. М., & Va, T. (2022) · Cells · doi:10.3390/cells11203235 · Cited by 14
“To date, there is no simple answer; data is currently accumulating [130,131].”
BackgroundSingh, M. K., & Thase, M. E. (2025) · CNS Spectrums · doi:10.1017/s1092852925000094 · Cited by 18
“IPSCs offer a reproducible method for modeling human diseases, 134 and in some conditions, iPSCs models have demonstrated aspects of the intended disease compared with controls.”
Preclinical Models for Studying Fuchs Endothelial Corneal Dystrophy
Sun, F., Xi, L. W. Q., Luu, W., Enkhbat, M., Neo, D. J. H., Mehta, J. S., Peh, G. S. L., & Yim, E. K. F. (2025) · Cells · doi:10.3390/cells14070505 · Cited by 13
“Induced pluripotent stem cells (iPSCs)-derived cells have been used for disease modeling, drug development, and cell therapy [131].”
Farboud, S. P., Fathi, E., Valipour, B., & Farahzadi, R. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05499-8 · Cited by 18
“Human induced pluripotent stem cells (hiPSCs) and their derivatives provide a suitable supply of human cells and have been used in a number of scientific domains, including the modeling of illness and the identification of new drugs [8].”
BackgroundInfluentialSynergistic potential of stem cells and microfluidics in regenerative medicine
Rajalekshmi, R., & Agrawal, D. K. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05108-8 · Cited by 14
LeBlang, C. J., Pazyra‐Murphy, M. F., Silagi, E. S., Dasgupta, S., Tsolias, M., Miller, T., Petrova, V., Zhen, S., Jovanovic, V. M., Castellano, D., et al. (2025) · Stem Cell Reports · doi:10.1016/j.stemcr.2025.102639 · Cited by 12
Non-apoptotic regulated cell death in Fuchs endothelial corneal dystrophy
Sakakura, S., Inagaki, E., Sayano, T., Yamazaki, R., Fusaki, N., Hatou, S., Hirayama, M., Tsubota, K., Negishi, K., Okano, H., et al. (2023) · Regenerative Therapy · doi:10.1016/j.reth.2023.11.001 · Cited by 8
“However, since cell death analysis using immortalized cell lines may not accurately re fl ect the pathophysiology, we used CECs induced from iPSCs in this study. iPSC-derived cells are widely used for disease modeling and drug development [32,33].”
MethodHypoimmunogenic pluripotent stem cells: A game-changer in cell-based regenerative medicine
Sarabi, P. A., Rismani, E., Shabanpouremam, M., Hendi, Z., Nikoubin, B., Rahimi, S., Taleb, M., Khosravi, A., Zarrabi, A., Hassan, M., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115134 · Cited by 8
Currently Used Methods to Evaluate the Efficacy of Therapeutic Drugs and Kidney Safety
Huang, H.-J., Chou, C., Tin, S. T., Liu, W.-C., Yang, H.-C., Lin, Y., Zheng, C., & Chiu, H. (2023) · Biomolecules · doi:10.3390/biom13111581 · Cited by 11
Yasmin, I. A., Dharmarajan, A., & Warrier, S. R. (2023) · Cancers · doi:10.3390/cancers15143622 · Cited by 11
“iPSCs overcome the problems that arose from differences between human and animal systems [8].”
BackgroundLiu, H., Zhu, M., Ding, W., Ning, L., & Qin, T. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.156489 · Cited by 6
Beckenkamp, L. R., da Silva, C. G., Immig, M. L., & Ogliari, K. S. (2024) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szae010 · Cited by 7
“…mechanisms and screening potential drugs, potentially reducing the time and resources required to develop personalized treatment strategies, 11,12 as well as cell products derived from patient-specific iPSCs to treat numerous diseases with a lower risk of immune rejection, thereby reducing…”
BackgroundGrigor’eva, E. V., Karapetyan, L. V., Malakhova, A. A., Medvedev, S. P., Minina, J. M., Hayrapetyan, V., Vardanyan, V., Zakian, S. M., Arakelyan, A., & Zakharyan, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116102 · Cited by 5
“Research related to the establishment of patient-derived iPSCs is expected to be a promising avenue for elucidating the pathogenesis of the disease, disease therapy, and drug discovery [33].”
BackgroundMahmoud, M. B., Rátkai, A. E., Bauer, K., Bencsik, N., Szűcs, A. L., Schlett, K., & Tárnok, K. (2025) · Scientific Reports · doi:10.1038/s41598-024-81140-4 · Cited by 9
Cell Transdifferentiation: A Challenging Strategy with Great Potential
Wang, F., Li, R., Zhang, L., Nie, X., Wang, L., & Chen, L. (2023) · Cellular Reprogramming · doi:10.1089/cell.2023.0015 · Cited by 5
“In contrast to ESCs, iPSCs can be differentiated into phenotypic cells, such as cardiac and neuronal cells, without ethical concerns (Kwok et al., 2022; Nicholson et al., 2022).”
Regulation of atrial and ventricular cardiomyocyte identity
Guo, S., Liu, Y., Ryan, A., Serrano, A. L. L., Deschênes, I., Jang, J., & Li, D. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.08.010 · Cited by 3
Capuzzo, A. M., Ossanna, R., Sierra, L. A. Q., Virla, F., Negri, A., Conti, A., Sbarbati, A., & Veronese, S. (2023) · Biochemistry · doi:10.5772/intechopen.110572 · Cited by 4
Stem cell therapy in retinal diseases: current evidence
Rubinato, L., Zan, E. R. D., Sarao, V., Veritti, D., & Lanzetta, P. (2023) · Expert Review of Ophthalmology · doi:10.1080/17469899.2023.2296895 · Cited by 4
“These iPSCs can be differentiated into retinal cells, providing a valuable platform for studying disease mechanisms, testing therapeutic interventions, and identifying potential drug candidates [12].”
BackgroundXiao, R., Chen, Y., Hu, Z., Tang, Q., Wang, P., Zhou, M., Wu, L., & Liang, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073635 · Cited by 5
Christowitz, C., Olivier, D. W., Schneider, J. W., Kotze, M. J., & Engelbrecht, A. (2024) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2024.108492 · Cited by 4
Dinasarapu, A. R., Sutcliffe, D. J., Grychowski, L., Ozel, E., Thite, A., Visser, J. E., Hess, E. J., Kolk, S. M., & Jinnah, H. A. (2025) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szaf032 · Cited by 4
Thomas, L., Rana, S., Duong, A., Kirkham, A. M., Shorr, R., Maganti, H. B., Seftel, M. D., & Allan, D. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.09.008 · Cited by 2
Yogitha, P. S., & Suchitra, M. R. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-11022-3 · Cited by 3
“Besides, the patient-specific nature of the models allows for testing therapies in stratified sub-groups [48, 49], and their scalability opens up the possibility of modelling rare diseases and the creation of biobanks.”
Dinasarapu, A. R., Sutcliffe, D. J., Ozel, E., Thite, A., Grychowski, L., Visser, J. E., Hess, E. J., Kolk, S. M., & Jinnah, H. A. (2025) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szaf065 · Cited by 3
Moseki, M. C., Makhzoum, A. B., Masisi, K., & Gaobotse, G. (2025) · Discover Biotechnology · doi:10.1007/s44340-025-00042-x · Cited by 4
“Notable successes include identifying drugs for familial dysautonomia and amyotrophic lateral sclerosis (ALS) using patient-specific iPSC models [15, 16].”
Stem Cell-Based Modeling Protocol for Parkinson’s Disease
Arjmand, B., Hamidpour, S. K., Aghayan, H. R., Alavi-Moghadam, S., Arjmand, R., Rezaei–Tavirani, M., Goodarzi, P., Nasli‐Esfahani, E., & Nikandish, M. (2023) · Methods in molecular biology · doi:10.1007/7651_2022_473 · Cited by 2
Sánchez-Florentino, Z. A., Romero-Martínez, B. S., Flores‐Soto, E., Serrano, H., Montaño, L., Valdés‐Tovar, M., Calixto, E., Aquino‐Gálvez, A., López-Riquelme, G. O., Alvarado, R., et al. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5331 · Cited by 3
“Both hONE cells and iPSc have moderate or high proliferative capacity while iN cells do not possess this capacity (5,56).”
BackgroundA Titin Missense Variant Causes Atrial FibrillationPreprint
Pavel, M. A., Chen, H., Hill, M., Sridhar, A., Barney, M., DeSantiago, J., Owais, A., Sandu, S., Darbar, F. A., Ornelas-Loredo, A., et al. (2025) · eLife · doi:10.7554/elife.104719.1 · Cited by 3
An overview of stem cell application in regenerative medicine
Riaz, F., Asgharzadeh, F., Binabaj, M. M., Ghalami, S., Saeinasab, M., & Sefat, F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-34152-6.00004-4 · Cited by 1
Cell-based immunotherapy for neurodegenerative disease: A promising avenue
Huerta, T. J., Urbina-Muñoz, V., Urra-Alvarez, V., Villablanca, C., Gómez‐Pérez, L. S., Saavedra, B., Contreras, T., & Vidal, R. L. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00816 · Cited by 2
An Optimized Protocol for piggyBac-Induced iPSC Generation from hPBMCs by Automatic Electroporation
Kılıç, P., & Coşar, B. (2023) · Methods in molecular biology · doi:10.1007/7651_2023_500 · Cited by 1
Pavel, M. A., Chen, H., Hill, M., Sridhar, A., Barney, M., DeSantiago, J., Baskaran, A., Owais, A., Sandu, S., Darbar, F. A., et al. (2026) · eLife · doi:10.1101/2024.12.06.24318402 · Cited by 4
Self-amplifying RNA enables rapid, durable, integration-free programming of hiPSCsPreprint
Santina, C. M. D., Ploessl, D. S., Lindsay‐Mosher, N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.24.684179 · Cited by 1
“Modified mRNA (modRNA) supports applications where transient expression is sufficient [1], [3], [4], [6], [7], [8], [9], but requires multiple transfections to achieve durable responses, limiting scalability and compromising cell viability [10], [11], [12], [13].”
A Titin Missense Variant Causes Atrial FibrillationPreprint
Pavel, M. A., Chen, H., Hill, M., Sridhar, A., Barney, M., DeSantiago, J., Baskaran, A., Owais, A., Sandu, S., Darbar, F. A., et al. (2025) · eLife · doi:10.7554/elife.104719.2 · Cited by 2
Xu, H. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9980
High-throughput measurements of neuronal activity in single human iPSC-derived glutamate neuronsPreprint
Gameiro‐Ros, I., Tengölics, Á. J., Prytkova, I., Kamarajan, C., Pang, Z. P., Goate, A., Hart, R. P., & Slesinger, P. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.07.646449
“Numerous laboratories and pharmaceutical companies are using iPSC-derived human neurons to study the etiology of various neurological and psychiatric disorders as well as to develop novel therapies 23 .”
iPSC-derived neurospheres: A cellular platform for Tau and Alzheimer’s disease immunotherapy
Chinnathambi, S., Adityan, A., Chandrashekar, M., & Velmurugan, G. (2025) · Advances in immunology · doi:10.1016/bs.ai.2025.11.001 · Cited by 1
O’Connor, K. C., Stanley, H. J., Bunnell, B. A., et al. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1734717
Uncovering NMDA receptor-mediated high firing activity in excitatory human neurons
Gameiro‐Ros, I., Tengölics, Á. J., Prytkova, I., Kamarajan, C., Pang, Z. P., Goate, A., Hart, R. P., & Slesinger, P. A. (2026) · iScience · doi:10.1016/j.isci.2026.115061 · Cited by 2
Cheng, Y., Xu, J., Wen, J., et al. (2026) · Stem Cell Research · doi:10.1016/j.scr.2026.103954
Self-citationMaksimova, M. V., Lechner, R. L., van Delden, J. J. M., & van Thiel, G. J. M. W. (2026) · Journal of Bioethical Inquiry · doi:10.1007/s11673-025-10529-1
Spatial patterning of biomimetic signals in corneal regeneration
Xi, L. W. Q., Look, Z., Bonnet, C., Maalhaghfard, M., González, S., Shnayder, G., Riau, A. K., Peh, G. S. L., Deng, S. X., Yim, E. K. F., et al. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115905
Amalina, T. N., Alsagaff, H., Sofa, S. L., Shofiyah, S., Sunaryo, B. F., Lova, K., Zakky, A., Febrianto, H., & Azis, R. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12587-z
Self-amplifying RNA enables rapid, durable, integration-free programming of hiPSCs
Santina, C. M. D., Ploessl, D. S., Lindsay‐Mosher, N., Brown, C. G., Ehmann, M. E., Blanch-Asensio, A., Kim, E. C., Boyden, E. S., Galloway, K. E., & Boyer, L. A. (2026) · Cell Reports Methods · doi:10.1016/j.crmeth.2026.101602 · Cited by 2
Lee, H., Desai, R., Kim, B., & Kim, D. (2026) · Advanced Intelligent Systems · doi:10.1002/aisy.70552
From Primary Cells to Organoids: Expanding the Biological Relevance of In Vitro Cellular Models
Deng, F., Wang, Y., Castellano, L. A., & Zhao, C. (2026) · Cells · doi:10.3390/cells15191741
Duvert, L., Garcia‐Castillo, L., Murru, C., Casanova, A., Ferry, D., Perrin, P., Coste, S., Bigot, A., Alloncle, A., Magdinier, F., et al. (2026) · Advanced Science · doi:10.1002/advs.78129
“The issue is underlined by the failure of over 90% of new drugs tested on animals during clinical trials [ 57 ], making the need to develop reliable human disease models even more evident.”
Metadata
- Authors
- Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H.
- Affiliations
- Institute of Biomedical Sciences, Academia Sinica (TW)
- Corresponding author
- Hsieh, Patrick C. H.
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2022-06-06
- Volume
- 11
- Issue
- 11
- Pages
- 1853
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9180434
- OpenAlex
- W4281701292
- Cited by
- 65
- References
- 132
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 15 · 2023: 17 · 2022: 2
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- induced pluripotent stem cells, iPSC-derived cardiomyocytes, iPSC-derived neurons, disease modeling, drug development, cell therapy, regenerative medicine
- MeSH terms
- Drug Development, Animals, Pluripotent Stem Cells, Regenerative Medicine, Induced Pluripotent Stem Cells, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
